U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11311 - 11320 of 13501 results

Status:
Investigational
Source:
INN:prisotinol [INN]
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Prisotinol is aminoalkyl-5-pyridinol patented by Ciba-Geigy A.-G. for treatment of angina pectoris. Prisotinol was studied in phase II clinical trials as a cardioprotective agent.
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:levometiomeprazine [INN]
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Levometiomeprazine is antiemetic, neuroleptic agent.
Status:
Investigational
Source:
INN:sardomozide [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Sardomozide (previously known as SAM486A or CGP-48664) was developed as an inhibitor of S-adenosyl-methionine-decarboxylase, a key enzyme for polyamine biosynthesis. Sardomozide possessed the broad-spectrum antiproliferative and antitumor activity. The drug participated in a phase II clinical trial as a monotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma. In Phase II clinical trial in patients with metastatic melanoma, the drug didn’t have significant therapeutic potential. The further development of this drug was discontinued.
Status:
Investigational
Source:
NCT02655601: Phase 2 Interventional Active, not recruiting High Grade Glioma
(2018)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
INN:tetriprofen
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Status:
Investigational
Source:
INN:tetriprofen
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Status:
Investigational
Source:
INN:tetriprofen
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Status:
Investigational
Source:
NCT01807910: Early Phase 1 Interventional Withdrawn Obesity
(2013)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Showing 11311 - 11320 of 13501 results